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Background: Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for
over 40 years. Recent trials of therapies that target-defective DNA maintenance using poly (ADP-ribose) polymerase (PARP)
inhibitors are showing promising results, yet invariably patients recur and succumb to disease. Mechanisms of resistance to
platinum-based and PARP inhibitor therapy in other cancer types include secondary mutations, which restore the integrity of DNA
repair through an increasing number of different mechanisms.
Methods: Here we present a case of a 63-year-old female patient with a germ line pathogenic BRCA2 mutation (6714 deletion)
who developed pancreatic cancer and had an exceptional response to platinum and PARP inhibitor therapy. Through next-
generation sequencing and clinical follow-up, we correlated tumour response and resistance to the BRCA2 mutational status in
the tumour.
Results: Initially, the patient had an exceptional response to platinum and PARP inhibitor therapy, most likely due to the BRCA2
mutation. However, the primary lesion recurred while on PARP inhibitor therapy and contained a secondary mutation in BRCA2,
which mostly likely restored BRCA2 function in PARP inhibitor-resistant tumour cells.
Conclusions: To our knowledge, this is the first report of a BRCA2 reversion mutation that conferred resistance to PARP inhibitor-
based therapy in a pancreatic ductal adenocarcinoma patient. Future studies are needed to understand this important mechanism
of resistance and how it may impact the choice of therapy for patients with pancreatic cancer.
Emerging data suggest that the subgroup of pancreatic ductal
adenocarcinoma (PDA) patients whose tumours harbour defects in
genes involved in the homologous recombination pathway, most
notably BRCA1 and BRCA2 mutations, may benefit significantly
from poly (ADP-ribose) polymerase (PARP) inhibitor-based
therapy (Lowery et al, 2011; Pishvaian et al, 2013; O’Reilly et al,
2014; Kaufman et al, 2015). From a personalised therapy
perspective, this patient cohort is sizable as previous reports claim
a conservative 5–7% of PDAs harbour mutations in the BRCA
pathway, whereas more recent sophisticated interrogations of PDA
genomes estimate that up to 20% of PDA have defects in DNA
damage response, which may confer sensitivity to platinum
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therapy and drugs that specifically target these mechanisms
(PARP, ATR, and Wee1 inhibitors; Waddell et al, 2015; Bailey
et al, 2016). In fact, ongoing clinical trials have revealed that
patients with BRCA-mutated PDAs are experiencing progression-
free survival times of 12 months or more, with frank response rates
of over 50%. Unfortunately these patients’ tumours eventually
develop resistance to PARP inhibitor-based therapy.
Pancreatic ductal adenocarcinoma cells altered in the DNA
repair genes, BRCA2, FANCC, and G (labelled as ‘BRCA-deficient’),
are all hypersensitive to inter-strand cross-linking agents and
platinum-based drugs in in vitro and in vivo models (van der
Heijden et al, 2005). Ashworth and colleagues showed that cells
deficient in genes involved in homologous recombination repair
pathway of double-stranded breaks (including BRCA1, BRCA2,
RAD51, RAD54, DSS1, RPA1, NBS1, ATR, ATM, CHK1, CHK2,
FANCD2, FANCA, or FANCC) are also hypersensitive to PARP
inhibitors (Farmer et al, 2005; McCabe et al, 2006). Hence, PARP
inhibitors are being investigated as a therapeutic option for various
cancers disrupted in the BRCA pathway, and the PARP inhibitor
olaparib (Lynparza, Astra Zeneca, Cambridge, UK) was recently
approved for BRCA-mutated ovarian cancer.
Poly (ADP-ribose) polymerase is a nuclear enzyme that plays a
critical role in the repair of DNA damage (McCabe et al, 2006;
Donawho et al, 2007; Kummar et al, 2009). Thus, PARP inhibition
results in less efficient DNA repair following a cytotoxic insult.
Consequently, PARP inhibitors act as sensitising agents for a
variety of DNA-damaging chemotherapeutic agents and with
radiotherapy. Veliparib (ABT-888, Abbvie Inc., Lake Bluff, IL,
USA) is a PARP inhibitor that has proven in vivo activity
(Kummar et al, 2009), and increases the sensitivity of tumour cells
to chemotherapy, including cisplatin, irinotecan, and temozolo-
mide, and to radiation (Curtin et al, 2004; DePinho and Polyak,
2004; Langelier et al, 2008; Sharpless and DePinho, 2004). Thus,
there are currently dozens of ongoing clinical trials of PARP
inhibitor-based combination therapies (Clinical trials.gov).
Since the mid-2000s, PARP inhibitor-based therapies have
shown promising results in patients with BRCA-mutated cancers
(Audeh et al, 2010; Fong et al, 2010; Tutt et al, 2010; Gelmon et al,
2011; Lowery et al, 2011; Kaye et al, 2012; Ledermann et al, 2012;
Sandhu et al, 2013; Kaufman et al, 2015; Mateo et al, 2015; Oza
et al, 2015). For example, Audeh et al (2010) demonstrated that
patients with BRCA-mutated recurrent ovarian cancer had a 33%
response rate to single agent olaparib dosed at 400mg twice daily.
Similar results were published by Fong et al (2010), though in their
cohort of BRCA-mutated ovarian cancer patients, the response rate
in platinum-sensitive disease was 61%. Herein, we present a case
report of a PDA patient with a germ line BRCA2mutation who was
selected for PARP inhibitor-based therapy.
METHODS AND RESULTS
Our patient is a 63-year-old female who was diagnosed with
pancreatic cancer when she initially presented with nausea,
vomiting, abdominal pain, and jaundice in April 2014. She had a
strong family history of cancer, with her brother having had breast
cancer, and her mother having breast cancer and uterine cancer,
and her father having prostate cancer. The patient had previously
chosen to undergo germ line testing (from a buccal swab) through
Myriad on 22 April 2010, which demonstrated a deleterious 6714
deletion mutation in BRCA2. An MRI on 03 April 2014 revealed a
1.7 2.1 cm mass in the head of the pancreas, and the patient was
referred to Johns Hopkins University Hospital for evaluation.
A pancreas protocol CT scan obtained for staging revealed a
localised tumour with no vessel involvement. She enroled in a pre-
operative trial of a short course of vaccine (GVAX) therapy with 7
days of oral cyclophosphamide (50mg daily) pre-operatively. Then
on 01 May 2014, the patient underwent surgical exploration for an
intended pancreaticoduodenectomy. Unfortunately, intra-opera-
tively, she was found to have metastatic disease to the liver, which
was proven on an intraoperative frozen section. The liver lesion
was excised and sent to Foundation Medicine for next-generation
sequencing of cancer-related genes (Foundation ONE test), the
results of which revealed a pathogenic BRCA2 mutation
(c.6486_6489delACAA p.K2162fs*5), a four base pair deletion
that resulted in a premature STOP codon (Figure 2). Careful
review of the BRCA2 mutation identified in the tumour specimen
by Foundation Medicine (and discussion with Foundation
Medicine) have confirmed that the specific mutation was the
same as the patient’s germ line BRCA2 mutation identified on the
buccal swab. Of note, an assessment of the mutational allele
frequency (MAF) revealed that the MAF of the BRCA2 mutation
was 61% – thus a higher allele frequency than would be expected
for a purely heterozygous state, and suggesting that there was loss
of heterozygosity in a portion of the cancer cells. However, because
the tested sample was not of isolated tumour cells, adjacent stromal
cell contamination may have affected the MAF results, and the
MAF purely in the tumour cells may actually have been higher
than 61%. The tumour also exhibited a KRAS G12V and a TP53
mutation (P295fs*50) both typical for pancreatic adenocarcinomas.
After recovery from surgery, the patient was seen at Georgetown
University for enrolment in an IRB-approved Phase I/II trial of
5-FU, oxaliplatin, and veliparib (NCT01489865). Her pre-treatment
CA 19-9 was 31.5, and her baseline imaging revealed a pancreatic
head mass 1.7 cm 1.7 cm, as well as a left lobe liver lesion,
2.3 cm 2.0 cm (Figure 1A, baseline imaging). The treatment
consisted of the standard modified FOLFOX6 regimen with
oxaliplatin (85mgm 2) Day 1, and continuous infusion 5-fluorouracil
(2400mgm 2) Days 1–3 but without the 5-fluorouracil bolus. She
also received veliparib 200mg orally twice a day for 7 days, and the
cycles were repeated every 2 weeks. Our patient began therapy on
05 June 2014, and had a fair degree of nausea and vomiting,
ultimately requiring the dose of veliparib to be reduced by 50%, to
100mg twice a day. She also had to stop the oxaliplatin after Cycle
13 for neuropathy. Nevertheless, the patient stayed on therapy for
31 cycles, through 10 August 2015 (progression-free survival¼ 15
months). While on study, she experienced a near complete
response, with a virtual radiographic disappearance of the liver
lesion and pancreatic head lesion by 23 March 2015 (Figure 1B,
near complete response imaging). Then, starting 18 May 2015, her
imaging revealed renewed progression of the pancreatic head mass.
Interestingly, the re-growth, in retrospect, was eccentric, when
compared to the primary pancreatic mass, visually suggesting
growth of an independent, resistant clone on the periphery
(Figure 1C and D, emerging resistance imaging).
Per RECIST criteria, the patient had developed progressive
disease by 10 August 2015, but her disease burden was still
minimal, and there was no evidence of extrapancreatic disease. On
the basis of the lack of development of additional liver lesions and
the response to systemic therapy, the patient underwent surgical
exploration on 10 September 2015 at the Johns Hopkins University
Hospital with the intent of performing a pancreaticoduodenect-
omy. The only identifiable liver lesion was resected and found to be
scar tissue on intraoperative frozen section. As a result of these
intraoperative findings the patient underwent a margin-negative
pancreaticoduodenectomy at that time. Final pathology revealed a
primary pancreatic adenocarcinoma with 3 out of 24 local lymph
nodes positive for disease. Final pathology confirmed only scar
within the liver lesion. She had an unremarkable recovery from the
operation.
After resection, due to the patient’s reluctance to have additional
cytotoxic chemotherapy she initiated olaparib as a maintenance
strategy in place of cytotoxic adjuvant therapy. She was treated at
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400mg orally twice a day, but quickly needed to reduce the dose to
200mg twice a day due to nausea and fatigue. During this time, the
resection specimen was re-sent to Foundation Medicine, which
again reported the original mutations (including the identical
KRAS and TP53 mutations), but also revealed a new somatic
(secondary) BRCA2 mutation (c.6448_6473delAAAGTTTCTCCA
TATCTCTCTCAATT p.K2150fs*17). This somatic 26 base dele-
tion in the BRCA2 gene was located 13 bases upstream of the germ
line 4 base pair deletion of the same allele. This secondary somatic
deletion restored the reading frame of the BRCA2 gene, which
contained the four base deletion (Figure 2). Interestingly, the MAF
of the secondary mutation from the pancreatic resection specimen
was only 8%, whereas the MAF of the germ line BRCA2 mutation
was reduced to 52%. These results suggest that only a relatively
small portion of the mutated alleles harboured this secondary
mutation. Clinically, immediately following the pancreaticoduode-
nectomy, there was no evidence of recurrent metastatic disease and
the functional consequences of this secondary mutation in this
context were not known. That is, although the reading frame was
restored, there was no knowledge of whether this produced a fully,
or even hypo-functional BRCA2. As a consequence, olaparib was
continued. Unfortunately, by early January, 2016 the patient was
clearly becoming symptomatic, and imaging revealed early
peritoneal carcinomatosis, suggesting olaparib offered no control
of her disease. Thus, she was taken off therapy, and was able to
enrol in an immunotherapy trial of the combination of the CXCR2
antagonist, AZD5069, and durvalumab (NCT02499328). While on
study, she developed suppurative cholecystitis, and passed away on
24 May 2016.
CONCLUSIONS
Many PARP inhibitor resistance mechanisms have been proposed
(Montoni et al, 2013), but Sakai et al (2008) and Edwards et al
(2008) were the first to describe that BRCA2 reversion mutations
could confer resistance to PARP inhibitor-based therapy
(Ashworth, 2008). They demonstrated that the PDA cell line
CAPAN1 that has lost one copy of the BRCA2 gene and harbours a
c.6174delT mutation in the other, are exquisitely sensitive to potent
PARP inhibitors (McCabe et al, 2005). In the cell line, this
mutation was accompanied by a loss of the wild-type copy of the
BRCA2 gene, yet made a truncated protein B2000 amino acids.
This study, albeit in just one cell line, demonstrated that PARP
inhibitors targeted this BRCA2 genetic lesion by showing that
isogenic cells generated to become41000-fold resistant harboured
a secondary mutation, which restored the open reading frame of
the BRCA2 sequence, and thus restoring the DNA repair function
(i.e., RAD51 binding to the BRCA repeats; Ashworth, 2008).
Subsequently, others also demonstrated the presence of
secondary BRCA1/2 mutations that confer resistance to therapy
in BRCA1/2-mutated ovarian cancer patients, whose tumours had
become resistant to platinum-based therapies (Swisher et al, 2008;
A. Baseline MAY 2014
B. nearCR March 2015
C. Surveillance May 2015
D. Preoperative August 2015
Figure 1. Patient images. The baseline scans from 28 May 2014 revealed a liver lesion and pancreatic mass. These lesions slowly improved on
veliparib, 5-FU, and oxaliplatin therapy, and by 23 March 2015, the liver lesion was not visible, and the pancreatic mass was barely visible.
However, from May 2015 to August 2015, there was steady re-growth of what proved to be a resistant clone in the pancreas, eccentric from the
original mass.
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Norquist et al, 2011), and may occur through a variety of
mechanisms that would not be detected using NGS for selected
genes and may require whole-genome sequencing (Patch et al,
2015). Importantly, Sakai et al (2008) demonstrated that the
platinum-resistant, BRCA2 functionally reverted ovarian cancer cell
lines also demonstrate resistance to PARP inhibitor therapy.
Additional studies in breast and ovarian cancer patients described
the development of BRCA reversion and PARP inhibitor resistance
(Barber et al, 2013). Of note, Ang et al (2013) assessed response to
chemotherapy including platinum-based chemotherapy in patients
with PARP inhibitor (olaparib)-resistant ovarian cancer. Surprisingly,
these PARP inhibitor-resistant ovarian cancers retained sensitivity to
chemotherapies including platinums. However, these observations
were confounded by the fact that none of the PARP inhibitor-
resistant ovarian cancers were found to have BRCA reversion events,
thus providing evidence that other mechanisms may be at play such
as defects in drug transport or drug metabolism.
As our patient received several therapies, including those that
target similar mechanisms such as platinum and PARP inhibition,
it is difficult to be definitive. Yet it is reasonable that either the
platinum and/or the PARP inhibitor induced selection pressure on
the tumour to restore defective DNA damage response mechan-
isms. To our knowledge, this is the first report of a BRCA2
reversion mutation, which conferred resistance to PARP inhibitor-
based therapy in a PDA patient. Future studies are needed to
understand this important mechanism of resistance and how it
may impact the choice of therapy for patients with pancreatic
cancer. Central to this approach is the assessment of tumour
biopsies pre- and post treatment.
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Figure 2. Germ line and secondary BRCA2mutations in pancreatic cancer. (A) Location of mutations in exon 11 – note proximity. (B) The germ line
mutation with the deletion highlighted in yellow, with C showing the resultant transcript with a premature STOP codon. D shows the secondary
somatic mutation in normal BRCA2 sequence, with E showing the secondary mutation in the context of the germ line deletion with restoration of
the reading frame. The green box with arrow shows how the secondary mutation brings the coding region back into the correct reading frame. A
full colour version of this figure is available at the British Journal of Cancer journal online
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